Close

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Novo Nordisk and AWS Enter Strategic AI Partnership to Accelerate Drug Discovery

Novo Nordisk has announced a strategic partnership with Amazon...

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals

The Trump administration is preparing to announce a new...

Huawei Expands AI Drug Discovery Ambitions Amid Domestic Chip Push and Policy Support

Huawei intends to deepen its artificial intelligence partnerships with...
- Advertisement -

The first batch of Russia’s coronavirus vaccine Sputnik V has entered “civil circulation”, reports from state media claimed on Thursday. The first potential vaccine in the world is now available to public in the capital city of Moscow.

Although the reports have not yet been confirmed by authorities, Russia has repeatedly stressed on the development and distribution of the vaccine at the earliest.

Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.

Notably, Russian President Vladamir Putin has offered to provide the vaccine to United Nations staff for free.

“Russia is ready to offer UN workers the necessary, qualified help, and in particular we propose to supply our vaccine for free to employees of the organisation and its subsidiaries who volunteer for vaccination,” said Putin during his speech at this year’s UN General Assembly meeting.

The announcement came as only results from small early studies on Sputnik V vaccine have been published, raising concerns among some scientists that the vaccine isn’t ready yet for widespread use. This prompted worldwide memes about bizarre side effects of the vaccine candidate.

Russia also announced that it will supply India with 100 million doses of the COVID-19 vaccine via pharmaceutical major Dr Reddy’s Laboratories as soon as it receives regulatory approval.

Trials for the same could begin in India in the next few weeks and Dr Reddy’s is set to enroll at least 1,000 to 1,200 participants at multiple governments and private hospitals across the country.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Novo Nordisk and AWS Enter Strategic AI Partnership to Accelerate Drug Discovery

Novo Nordisk has announced a strategic partnership with Amazon...

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals

The Trump administration is preparing to announce a new...

Huawei Expands AI Drug Discovery Ambitions Amid Domestic Chip Push and Policy Support

Huawei intends to deepen its artificial intelligence partnerships with...

McKesson to Acquire Precision Medicine Group for $2.25 Billion

US-based healthcare services provider McKesson has agreed to acquire...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »